November 24, 2016 - By Linda Rogers · 0 Comments
The stock of Aradigm Corporation (NASDAQ:ARDM) registered an increase of 22.88% in short interest. ARDM’s total short interest was 43,500 shares in November as published by FINRA. Its up 22.88% from 35,400 shares, reported previously. With 22,500 shares average volume, it will take short sellers 2 days to cover their ARDM’s short positions. The short interest to Aradigm Corporation’s float is 0.61%. The stock decreased 0.38% or $0.02 on November 23, hitting $5.21. About 8,750 shares traded hands. Aradigm Corporation (NASDAQ:ARDM) has risen 6.33% since April 22, 2016 and is uptrending. It has outperformed by 0.92% the S&P500.
Aradigm Corporation is a pharmaceutical firm focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The company has a market cap of $79.11 million. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It currently has negative earnings. It offers AERx pulmonary drug delivery platform and other technologies.
Insitutional Activity: The institutional sentiment decreased to 0.8 in Q2 2016. Its down 0.45, from 1.25 in 2016Q1. The ratio worsened, as 3 funds sold all Aradigm Corporation shares owned while 1 reduced positions. 3 funds bought stakes while 2 increased positions. They now own 5.45 million shares or 0.52% less from 5.48 million shares in 2016Q1.
Focused Wealth Mgmt holds 0% or 2 shares in its portfolio. Deutsche Savings Bank Ag holds 0% of its portfolio in Aradigm Corporation (NASDAQ:ARDM) for 61,538 shares. Bancorp Of America Corporation De has 0% invested in the company for 28 shares. Tower Research Llc (Trc) accumulated 0% or 747 shares. Point72 Asset Mngmt Lp reported 320,585 shares or 0.01% of all its holdings. Evercore Wealth Mgmt Limited has 0% invested in the company for 2 shares. Great Point Partners Limited Liability holds 1.00M shares or 1.26% of its portfolio. Fmr Limited Liability has invested 0% of its portfolio in Aradigm Corporation (NASDAQ:ARDM). Goldman Sachs Grp holds 0% of its portfolio in Aradigm Corporation (NASDAQ:ARDM) for 16,385 shares. Blackrock Invest Limited Co has 1,598 shares for 0% of their US portfolio. Ladenburg Thalmann Fincl Serv accumulated 2 shares or 0% of the stock. Jacobs Levy Equity Management Inc last reported 0% of its portfolio in the stock. First Eagle Invest Management Ltd Llc last reported 0.04% of its portfolio in the stock. Livingston Grp Asset Mgmt (Operating As Southport Management) holds 0% or 1,000 shares in its portfolio. Blackrock Fund Advsrs last reported 0% of its portfolio in the stock.
Insider Transactions: Since October 4, 2016, the stock had 0 buys, and 1 sale for $2,859 net activity. $2,859 worth of Aradigm Corporation (NASDAQ:ARDM) was sold by Froehlich Juergen Kurt on Tuesday, October 4.
Aradigm Corporation, incorporated on January 30, 1991, is a specialty pharmaceutical firm focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. It is focused on commercializing its products in the United States, European Union (EU), Japan and China. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. The Firm offers AERx pulmonary drug delivery platform and other technologies. The Company’s partnered programs under development include Inhaled Ciprofloxacin. The Firm is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). The Firm is focused on inhaled nicotine product utilizing its AERx delivery system that is focused on addressing the acute craving for cigarettes and, through gradual reduction of the peak nicotine levels, could wean-off patients from cigarette smoking and from the nicotine addiction.
More recent Aradigm Corporation (NASDAQ:ARDM) news were published by: Businesswire.com which released: “Aradigm Corporation Announces First Closing of Private Placement Offering of …” on April 26, 2016. Also Seekingalpha.com published the news titled: “6 Reasons Aradigm Corporation Is An Excellent Risk Vs. Reward Opportunity” on August 08, 2014. Businesswire.com‘s news article titled: “Aradigm Corporation Completes Enrollment in the Second Phase III Study of …” with publication date: October 13, 2015 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers